companies / acurxpharma-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-06 json
| total_raised | 4,587,4734.6M | ○ |
|---|---|---|
| founded | 2017 | |
| hq | Staten Island, NY | |
| industry | unknown | |
| stage | null |
Acurx Pharmaceuticals is a clinical-stage biopharma developing a new class of antibiotics targeting bacteria listed as priority pathogens by the WHO, CDC, and FDA. It serves patients with serious resistant infections, with lead candidate ibezapolstat in trials. Its differentiator is a novel DNA polymerase IIIC inhibition mechanism.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-15 | Funding round | 4,587,4734.6M | null | ○ |
Apache HTTP Server, apache
| fact | status | src |
|---|---|---|
| Funding round, $4.6M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-25latest_round: seed, $4.6M, 2026-04-15 → Funding round, $4.6M, 2026-04-15, ○ 2026-05-06 | latest_round | seed, $4.6M, 2026-04-15 → Funding round, $4.6M, 2026-04-15 | ○ 2026-05-06 |
Records begin 2026-09-24. all_changes